General
Preferred name
AMBROXOL
Synonyms
AMBROXOL HYDROCHLORIDE ()
Mucoangin ()
Mucosolvan ()
Ambroxol HCl ()
P&D ID
PD055529
CAS
23828-92-4
15942-05-9
18683-91-5
Tags
natural product
drug
available
Drug indication
Bronchitis
Drug Status
approved
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Ambroxol stimulates the synthesis and release of surfactant in the respiratory tract and acts as a mucoactive/expectorant drug. This action appears to be associated with ambroxol's regulation of glucosylceramide levels, via modulation of non-lysosomal glucosylceramidase (GCase) beta 2 (GBA2; Q9HCG7). Ambroxol is reported to act as a small molecule chaperone for GCase proteins that can increase the stability and function of mutant and wild-type GCases in in vitro and in vivo models , and in clinical trial subjects . Ambroxol binds to nascent GCase proteins (at the enzyme active site) within the endoplasmic reticulum, and this action facilitates transport to the lysosome . The acidic lysosomal environment provokes ambroxol disassociation, leaving the enzyme free to function normally.
SARS-CoV-2 and COVID-19: Evidence presented in a preprint suggests that ambroxol (and its prodrug ) directly disrupts the protein-protein interaction between the SARS-CoV-2 spike protein and ACE2 . This action is reported to inhibit the cytopathic effects induced by SARS-CoV-2 infection in vitro, which is suggestive of potential prophylactic and/or therapeutic use of these drugs against COVID-19. (GtoPdb)
SARS-CoV-2 and COVID-19: Evidence presented in a preprint suggests that ambroxol (and its prodrug ) directly disrupts the protein-protein interaction between the SARS-CoV-2 spike protein and ACE2 . This action is reported to inhibit the cytopathic effects induced by SARS-CoV-2 infection in vitro, which is suggestive of potential prophylactic and/or therapeutic use of these drugs against COVID-19. (GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
6
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
22
Molecular Weight
375.98
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
3
Ring Count
2
Aromatic Ring Count
1
cLogP
3.19
TPSA
58.28
Fraction CSP3
0.54
Chiral centers
0.0
Largest ring
6.0
QED
0.71
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Source data
